All News
Pregnancy outcomes in autoinflammatory disease
EurekAlert!
To address this, a French multi-centre prospective pregnancy observational cohort was set up, to analyse disease activity, treatment, pregnancy outcomes, delivery, and neonatal health.
Read Article
From Domains to Decisions: Personalizing PsA Care with Data
At EULAR 2025, Dr. Laura Coates (Oxford) took the plenary stage to reframe how we think about treating psoriatic arthritis. The message was clear: in 2025, PsA treatment is no longer about following a linear algorithm; it’s about understanding the unique constellation of domains, comorbidities, and patient factors that shape each clinical decision.
Read Article
Psoriatic Arthritis: Hit hard and Early
Two studies found no significant benefit of early biologics over standard methotrexate treatment, but they did not focus on poor prognosis cases. The SPEED trial, funded by the NIHR, aimed to compare disease activity in 192 PsA patients https://t.co/Vte0RSyszN
Dr. John Cush RheumNow ( View Tweet)
Health inequities in rheumatology: A central theme
This year at EULAR, health inequalities have taken centre stage as fundamental drivers of outcomes in rheumatic and musculoskeletal diseases (RMDs). Across multiple sessions and studies, delegates are presenting compelling https://t.co/nmdyJYQV0B
Dr. John Cush RheumNow ( View Tweet)
⌛️ Diagnostic delay in #SpA: Better with time?
🔹️Data from the @Official_ASAS
Study
🔹️4339 patients
🔹️Delay decreased over time
🔹️Same trends across world regions & across Human Development Index categories
POS0908 #EULAR2025
@RheumNow https://t.co/Y9gxQDV9KJ
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2025 Abstr#POS0318 Single timepoint assessment may not show true picture of #SLE control. Data from BILAG-BR registry using machine learning showed 6 trajectories with clinical meaning:
-Nonresponse with high activity: dsDNA-ve & RNP+
-Response-flare: active MSK @RheumNow https://t.co/VrI8e4ONtM
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Psoriatic Arthritis at Risk for Interstitial Lung Disease
A TriNetX EHR study shows that psoriatic arthritis (PsA), but not Psoriasis (PsO), patients are at increased risk for interstitial lung disease (ILD).
https://t.co/2zuxF1PY3Q. https://t.co/Icck4qE76X
Dr. John Cush RheumNow ( View Tweet)
#EULAR2025 Abstr#OP0204 Limitations of #SLE Damage Index (SDI): outdated items definition, missing item & unclear use in children. Revised SDI (SLICC-ACR-LFA) via data-driven and expert patient-doctor consensus is underway. Next steps: validation and including weighting @RheumNow https://t.co/K5rPgXBPrj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
ARIAA study: longer-term data now
High-risk ACPA+ clinically suspect arthralgias
abatacept for 6mo, then stop altogether
Really impressive long-term effect
also noting success of APIPPRA, abatacept flicks off some very early RA, at least for a while
#EULAR2025 OP0325 @RheumNow https://t.co/AeRrUKPPiK https://t.co/jtynyD0ioO
Links:
David Liew drdavidliew ( View Tweet)
Why do people not respond to psoriatic arthritis therapies?
#EULAR2025 @RheumNow https://t.co/VGLN0R3TyY
David Liew drdavidliew ( View Tweet)
POETYK PsA-1
Deucravacitinib TYK2i RCT Ph 3
ACR 20 DEU 54% vs. 34% PBO wk 16
ACR 50 DEU 23% vs. 14% PBO
also significant diff for HAQ-DI PASI 75 SF-36 PCS and MDA
Less Rx progression
@RheumNow #EULAR2025 LB0001 https://t.co/oRLlHwI4Bh
Aurelie Najm AurelieRheumo ( View Tweet)
RCT of a digital intervention in RMDs? It was long awaited, and all the lights are green🟢!
German national Bechterew-App RCT of
App based intervention AXIA, control group was standard of care
200pts 12wks
ASAS20 response 51% vs. 9%
ASAS40 response rate 23% vs. 3%
BASDAI:
Aurelie Najm AurelieRheumo ( View Tweet)
📊 In POETYK PsA-1, deucravacitinib (TYK2i) significantly improved ACR20 at W16 (54% vs 34% placebo) in bDMARD-naive PsA.
Also improved QoL, skin, and MSK outcomes.
Post hoc: slowed radiographic progression.
Well tolerated & no new safety signals
@RheumNow #EULAR2025 #LB0001
Mrinalini Dey DrMiniDey ( View Tweet)
📱 Axia, a digital therapeutic for #axSpa, led to significant improvements in BASDAI, BASFI & ASQoL in a 12-week RCT.
ASAS20: 51% vs 9%; ASAS40: 23% vs 3%.
Promising app-based intervention comprising individualised exercise, pt education & disease Mx.
@RheumNow #EULAR2025 #LB0002
Mrinalini Dey DrMiniDey ( View Tweet)
Older adults with chronic MSK pain report lower physical health—but better mental health—than younger peers.
Fewer missed work days, too.
Is this resilience, adaptation, or shifting expectations with age?
POS0402 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
#EULAR2025 Abstr#LB0002 Crossover RCT of use of AXIA - a novel app-based intervention showed improvement in disease activity, functionality & quality of life in pople with Axial #SpA vs usual care. Available in Austria currently - awaiting rollout and in other languages @RheumNow https://t.co/nV4QifyikL
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Self-management of rheum disease is ripe for apps, gamification. How well does it work though?
This app (Axia) in axSpA was basically as good as a biologic.
Maybe you downplay non-pharm management, prob because we don’t do it well. This changes that
#EULAR2025 LB0002 @RheumNow https://t.co/sfhEJFsF89
Links:
David Liew drdavidliew ( View Tweet)
Presenting our abstract on remote monitoring in rheumatology at #EULAR2025 @RBNHSFT @UniofReading @HenleyBSchool @RheumNow https://t.co/palWjtX3gM
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Tapering in RA?
In SORAIRO (n=149), pts in remission on ozoralizumab+MTX:
🧪 49% became MTX-free
⏱ 80% spaced OZR to q8w
CDAI ≤10 maintained in >90% if baseline remission + albumin >3.8
LB0006 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
#EULAR2025 Abstr#POS1293 Our cohort study support non-medical switch from Rituximab originator to Biosimilar(RTX-B) or btw RTX-Bs in connective tissue disease. No difference in response/B-cell depletion pre- & post-switch.Only 10% stopped RTX at 5-year.Better than in RA @RheumNow https://t.co/ERPgwQ3gZB
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
